Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 28: 569-577, 1982;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daniels, L. B.
Right arrow Articles by Glew, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daniels, L. B.
Right arrow Articles by Glew, R. H.

Clinical Chemistry, Vol 28, 569-577, Copyright © 1982 by American Association for Clinical Chemistry

beta-Glucosidase assays in the diagnosis of Gaucher's disease

LB Daniels and RH Glew

The description in 1965 of glucocerebroside: beta-glucosidase as the enzymic defect in Gaucher's disease stimulated considerable research interest and effort toward establishing rapid, reliable, and inexpensive enzymic assays for diagnostic purposes and carrier detection. Here, we consider some of the methods currently in use in which the substrate is the synthetic glucoside, 4-methylumbelliferyl- beta-D-glucopyranoside, and leukocytes and fibroblasts are the sources of enzyme. We also consider the concepts of the "acid beta-glucosidase" and multiple forms of beta-glucosidase that have been proposed to explain the effectiveness of the fluorometric assays. Finally, we analyze the limitations of each method and discuss the difficulties involved in instituting heterozygote screening programs in the general population.


The following articles in journals at HighWire Press have cited this article:


Home page
 haematolHome page
M. de Fost, J. M.F.G. Aerts, J. E.M. Groener, M. Maas, E. M. Akkerman, M. G. Wiersma, and C. E.M. Hollak
Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial
Haematologica, February 1, 2007; 92(2): 215 - 221.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. de Fost, C. E. M. Hollak, J. E. M. Groener, J. M. F. G. Aerts, M. Maas, L. W. Poll, M. G. Wiersma, D. Haussinger, S. Brett, N. Brill, et al.
Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis
Blood, August 1, 2006; 108(3): 830 - 835.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. M. Danilov, J. Deinum, I. V. Balyasnikova, Z.-L. Sun, C. Kramers, C. E.M. Hollak, and R. F. Albrecht
Detection of Mutated Angiotensin I-Converting Enzyme by Serum/Plasma Analysis Using a Pair of Monoclonal Antibodies
Clin. Chem., June 1, 2005; 51(6): 1040 - 1043.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. G. McMahon, H. Nakano, M.-D. Levy, and J. F. Gregory III
Cytosolic Pyridoxine-beta -D-Glucoside Hydrolase from Porcine Jejunal Mucosa. PURIFICATION, PROPERTIES, AND COMPARISON WITH BROAD SPECIFICITY beta -GLUCOSIDASE
J. Biol. Chem., December 19, 1997; 272(51): 32025 - 32033.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by the American Association for Clinical Chemistry.